Lefetamine, a controlled drug and pharmaceutical lead of new designer drugs: synthesis, metabolism, and detectability in urine and human liver preparations using GC-MS, LC-MSn, and LC-high resolution-MS/MS
- 519 Downloads
Lefetamine (N,N-dimethyl-1,2-diphenylethylamine, L-SPA) was marketed as an opioid analgesic in Japan and Italy. After being widely abused, it became a controlled substance. It seems to be a pharmaceutical lead for designer drugs because N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA) were confiscated by the German police. In contrast to these derivatives, metabolism and detectability of lefetamine were not studied yet. Therefore, phase I and II metabolism should be elucidated and correlated to the derivatives. Also the detectability using the authors’ standard urine screening approaches (SUSA) needed to be checked. As lefetamine was commercially unavailable, it had to be synthesized first. For metabolism studies, a high dose of lefetamine was administered to rats and the urine samples worked up in different ways. Separation and analysis were achieved by gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-high resolution-tandem mass spectrometry (LC-HR-MS/MS). In accordance with NEPDA and NPDPA, the following metabolic steps could be proposed: N-oxidation, N-dealkylation, mono- and bis-hydroxylation of the benzene ring, and hydroxylation of the phenyl ring only after N-dealkylation. The di-hydroxy metabolites were conjugated by methylation of one hydroxy group, and hydroxy metabolites by glucuronidation or sulfation. All initial metabolites could also be detected in human liver preparations. After a therapeutic lefetamine dose, the bis-nor, bis-nor-hydroxy, nor-hydroxy, nor-di-hydroxy metabolites could be detected using the authors’ GC-MS SUSA and the nor-hydroxy-glucuronide by the LC-MSn SUSA. Thus, an intake of lefetamine should be detectable in human urine assuming similar pharmacokinetics.
KeywordsDrugs of abuse Lefetamine Metabolism GC-MS LC-HR-MS/MS
The authors thank Andreas Helfer, Markus Meyer, Julian Michely, Carsten Schröder, Christian Steuer, Gabriele Ulrich, and Armin A. Weber for their support and helpful discussions.
- 1.Expert Committee on Addiction-Producing Drugs (1961) Expert committee on addiction-producing drugs. Eleventh report. World Health Organ Tech Rep Ser 211:1–16Google Scholar
- 7.Westphal F, Junge T, Jacobsen-Bauer A, Rösner P (2010) Lefetamin-Derivate: alte Bekannte neu auf dem Drogenmarkt. Toxichem Krimtech 77:46–58Google Scholar
- 8.Wink CSD, Meyer GMJ, Wissenbach DK, Jacobsen-Bauer A, Meyer MR, Maurer HH (2014) Lefetamine-derived designer drugs N-ethyl-1,2-diphenylethylamine (NEDPA) and N-iso-propyl-1,2-diphenylethylamine (NPDPA): metabolism and detectability in rat urine using GC-MS, LC-MSn and LC-high resolution (HR)-MS/MS. Drug Test Anal 6:1038–1048CrossRefGoogle Scholar
- 9.Maurer HH, Pfleger K, Weber AA (2011) Mass spectral and GC data of drugs, poisons, pesticides, pollutants and their metabolites. Wiley-VCH, WeinheimGoogle Scholar
- 11.Maurer HH, Wissenbach DK, Weber AA (2014) Maurer/Wissenbach/Weber MWW LC-MSn library of drugs, poisons, and their metabolites. Wiley-VCH, WeinheimGoogle Scholar
- 14.Malz F (2003) Quantitative NMR-Specktroskopie als Referenzverfahren in der alaytischen Chemie. PhD thesis, Humboldt-Universität Berlin, BerlinGoogle Scholar
- 15.Meyer GMJ, Wink CSD, Zapp J, Maurer HH (2015) GC-MS, LC-MSn, LC-high resolution-MSn, and NMR studies on the metabolism and toxicological detection of mesembrine and mesembrenone, the main alkaloids of the legal high “Kanna” isolated from Sceletium tortuosum. Anal Bioanal Chem. doi: 10.1007/s00216-014-8109-9 Google Scholar
- 16.Maurer HH, Pfleger K, Weber AA (2011) Mass spectral library of drugs, poisons, pesticides, pollutants, and their metabolites. Wiley-VCH, WeinheimGoogle Scholar
- 19.McLafferty FW, Turecek F (1993) Interpretation of mass spectra. University Science Books, Mill ValleyGoogle Scholar
- 20.Smith RM, Busch KL (1999) Understanding mass spectra—a basic approach. Wiley, New YorkGoogle Scholar